And about David Suhy: Senior Vice President, Re

David Suhy
Appointed October 2012

David Suhy leads all of Tacere’s therapeutic development programs. He was one of the inventors of TT-033 and has directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through to Investigational New Drug (IND) enabling studies. Dr Suhy will continue to lead the program as TT-034 is poised to enter the clinic in 2013.

Dr Suhy has had significant experience in development of DNA-based constructs. His involvement in the TT-03x program started when he was a senior scientist at Avocel, an RNAi therapeutics company, which he joined in 2003 shortly after its inception. He continued TT-03x development after the company was acquired by Benitec Ltd. in 2004. In 2008 he returned to Tacere Therapeutics as Director of Research & Development after serving as the Associate Director of R&D at Clontech.

Dr Suhy has held other distinguished roles with US-based biotechnology companies. He served as Principal Scientist at Antara Biosciences, where he was developing two molecular diagnostics platforms, based on electrochemistry and RFID tags as chip-based nucleic acid detection modalities. He also led the Target Validation Group at PPD Discovery, a company with proprietary technology surrounding the use of genetic suppressor elements to identify ‘ druggable ’ genomic targets for large pharmaceutical companies.

Dr Suhy holds a BS in Biochemistry and Biophysics from the University of Pittsburgh, earned his PhD in Biochemistry, Molecular Biology and Cell Biology at Northwestern University, and conducted his post-doctoral work at Stanford University.

Dr Suhy was appointed to his present role with Tacere in October 2012.